Get all your news in one place.
100's of premium titles.
One app.
Start reading
The New Daily
The New Daily
Samantha Lock

Pharma firm claims drug trial slows Alzheimer’s progression by 35 per cent

Drug company Eli Lilly says its new Alzheimer's drug appears to slow symptoms of the disease. Photo: AP

A new drug given to Alzheimer’s patients slowed the disease’s progress by 35 per cent, the latest trial has revealed.

Patients with early stages of Alzheimer’s who were given the drug donanemab showed significantly slowed cognitive and functional decline over an 18-month phase-three trial, according to results published by pharmacutical company Eli Lilly on Thursday.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.